journal
MENU ▼
Read by QxMD icon Read
search

Hematological Oncology

journal
https://www.readbyqxmd.com/read/28444777/interphase-fish-for-bcr-abl1-rearrangement-on-neutrophils-a-decisive-tool-to-discriminate-a-lymphoid-blast-crisis-of-chronic-myeloid-leukemia-from-a-de-novo-bcr-abl1-positive-acute-lymphoblastic-leukemia
#1
Estelle Balducci, Marie Loosveld, Ilhem Rahal, John Boudjarane, Emilie Alazard, Chantal Missirian, Marina Lafage-Pochitaloff, Gérard Michel, Hélène Zattara
Discrimination between lymphoid blast crisis of chronic myeloid leukemia (CML) and de novo BCR-ABL1 positive acute lymphoblastic leukemia (ALL) represents a diagnostic challenge because this distinction has a major incidence on the management of patients. Here, we report an uncommon pediatric case of ALL with cryptic ins(22;9)(q11;q34q34) and p190-type BCR-ABL1 transcript. We performed interphase fluorescence in situ hybridization (FISH) for BCR-ABL1 rearrangement on blood neutrophils, which was positive consistent with the diagnosis of lymphoid blast crisis of CML...
April 25, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28429426/age-related-health-care-disparities-in-multiple-myeloma
#2
Mathieu Puyade, Gautier Defossez, François Guilhot, Xavier Leleu, Pierre Ingrand
Age is a well-known factor in solid tumours linked to lower adherence to guidelines. Scarce data exist for haematologic malignancies such as multiple myeloma (MM). The aim of the study was to investigate the relationships among age, adherence to guidelines in MM, and overall survival (OS).The Poitou-Charentes cancer registry has exhaustively registered incident cases of MM from 2008 to 2010. Diagnosis, staging, prognosis, and first-line treatment were compared to the international guidelines. Three hundred and sixty-seven patients aged 36 to 93 years were included...
April 21, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28401574/complete-metabolic-response-cmr-in-positron-emission-tomography-computed-tomography-pet-ct-scans-may-have-prognostic-significance-in-patients-with-marginal-zone-lymphomas-mzl
#3
Ji Hyun Park, Shin Kim, Jin Sook Ryu, Sang-Wook Lee, Chan-Sik Park, Jooryung Huh, Cheolwon Suh
Although clinical use of positron emission tomography-computed tomography (PET-CT) scans is well established in aggressive lymphomas, its prognostic value in marginal zone lymphoma (MZL) remains yet unclear. Hence, we investigated potential role of PET-CT in predicting MZL patients' outcomes following systemic chemotherapy. A total of 32 patients with MZL who received first-line chemotherapy were included in the analysis. They all underwent pretreatment, interim, and posttreatment PET-CT scans. The primary objective was to evaluate the role of complete metabolic response (CMR) in posttreatment PET-CT scans in predicting progression-free survival (PFS)...
April 11, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28401573/is-tocilizumab-a-potential-therapeutic-option-for-refractory-unicentric-castleman-disease
#4
Muhammad Bilal Abid, Rachel Peck, Muhammad Abbas Abid, Wesam Al-Sakkaf, Yuening Zhang, Giles S Dunnill, Konrad Staines, Iara-Maria Sequeiros, Lisa Lowry
Castleman disease is a rare lymphoproliferative disorder with 2 distinctly defined clinical forms. While multicentric Castleman disease (UCD) poses a potential therapeutic challenge, unicentric variant has historically been considered curable with surgical resection. Hence, little is known to guide management of patients with UCD, refractory to surgical resection and combination chemotherapy. We present a case of a patient, negative for HIV and HHV-8, who had an unsuccessful surgical intervention and no response to radiotherapy and chemotherapy...
April 11, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28397326/diagnosis-and-management-of-neuropathies-associated-with-plasma-cell-dyscrasias
#5
REVIEW
Evan Rosenbaum, Douglas Marks, Shahzad Raza
Neuropathies associated with plasma cell dyscrasias are a major cause of morbidity for patients managed by medical oncologists. Because of similarities in clinical presentation and on nerve conduction studies, identifying the underlying disease leading to a paraproteinemic neuropathy can often be difficult. In addition, the degree of neurologic deficit does not strictly correlate with the extent of abnormalities on common clinical laboratory testing. Fortunately, with increasing understanding into the biologic mechanisms of underlying hematologic diseases, additional biomarkers have recently been developed, thus improving our diagnostic capacity...
April 10, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28393378/how-in-depth-histological-look-may-allow-challenging-diagnosis-the-case-of-a-primary-in-situ-mantle-cell-neoplasm-of-the-appendix
#6
LETTER
Maria Raffaella Ambrosio, Massimo Granai, Giuseppe Lo Bello, Manuela Cirami, Lucia Mundo, Lorenzo Leoncini, Stefano Lazzi
No abstract text is available yet for this article.
April 9, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28393375/long-term-outcome-of-patients-with-solitary-plasmacytoma-treated-with-radiotherapy-a-population-based-single-center-study-with-median-follow-up-of-13-7%C3%A2-years
#7
Dlawer Abdulla Barzenje, Arne Kolstad, Waleed Ghanima, Harald Holte
In this single-center, population-based, and retrospective study, we analyzed the outcome of 49 patients with solitary bone plasmacytoma (SBP) and 28 patients with solitary extramedullary plasmacytoma (SEP), all treated with radiotherapy. Laminectomy was performed in 18/30 SBP patients with vertebral involvement and tumour resection in 10 SEP patients. Overall survival and cause of death for each patient were compared to 5 sex-, age-, and residency-matched individuals from the normal population. Response (complete and partial) was achieved in 94% of SBP and 96% of SEP patients...
April 9, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28378425/follicular-lymphoma-state-of-the-art-icml-workshop-in-lugano-2015
#8
REVIEW
Randy D Gascoyne, Bertrand Nadel, Laura Pasqualucci, Jude Fitzgibbon, Jacqueline E Payton, Ari Melnick, Oliver Weigert, Karin Tarte, John G Gribben, Jonathan W Friedberg, John F Seymour, Franco Cavalli, Emanuele Zucca
The 13th International Conference on Malignant Lymphoma held in Lugano in June 2015 was preceded by a closed workshop (organized in collaboration with the American Association for Cancer Research and the European School of Oncology) with the aim of developing an up-to-date understanding of the biology of follicular lymphoma and the clinical implications of new findings in the field. Discussed topics included the mutational spectrum at diagnosis, the clinical correlates of genetic and epigenetic alterations, the mechanisms of clonal evolution and histological transformation, the cross talk between tumor cells and microenvironment, and the development of novel treatments...
April 4, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28378367/clonal-evolution-detected-with-conventional-cytogenetic-analysis-is-a-potent-prognostic-factor-in-adult-patients-with-relapsed-aml
#9
Hiroaki Shimizu, Akihiko Yokohama, Takuma Ishizaki, Nahoko Hatsumi, Satoru Takada, Takayuki Saitoh, Toru Sakura, Yoshihisa Nojima, Hiroshi Handa
We retrospectively investigated 144 patients with relapsed acute myeloid leukemia (AML) to clarify predisposing factors and the prognostic impact of acquisition of additional cytogenetic abnormalities (ACA) at the first relapse. Additional cytogenetic abnormalities are recognized as clonal evolution at the cytogenetic level. Fifty-nine patients (41%) acquired ACA at the first relapse. The incidences of ACA acquisition varied depending on cytogenetic abnormalities at initial diagnosis. Multivariate analysis identified t(8;21), complex karyotype, and a duration of fewer than 12 months of complete remission as independent predisposing factors for ACA acquisition...
April 4, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28332735/non-hodgkin-lymphoma-in-south-east-asia-an-analysis-of-the-histopathology-clinical-features-and-survival-from-thailand
#10
Tanin Intragumtornchai, Udomsak Bunworasate, Kitsada Wudhikarn, Arnuparp Lekhakula, Jakrawadi Julamanee, Kanchana Chansung, Chittima Sirijerachai, Lalita Norasetthada, Weerasak Nawarawong, Archrob Khuhapinant, Noppadol Siritanaratanakul, Tontanai Numbenjapon, Kannadit Prayongratana, Suporn Chuncharunee, Pimjai Niparuck, Tawatchai Suwanban, Nongluk Kanitsap, Somchai Wongkhantee, Rutchanid Pornvipavee, Peerapon Wong, Nisa Makruasi, Pongsak Wannakrairot, Thamathorn Assanasen, Sanya Sukpanichnant, Paisarn Boonsakan, Wasana Kanoksil, Charin Ya-In, Kanita Kayasut, Winyu Mitranun, Naree Warnnissorn
Systemic reports on the descriptive epidemiology of non-Hodgkin lymphoma (NHL) from Southeast Asia are scarce. A nationwide multi-institutional registry was conducted to compare the histopathology, clinical features, and survival of Thai adult patients with NHL using large registries, especially those from Far East Asia (FEA). Using a web-based registry system, 13 major medical centers from the 4 geographic regions of Thailand prospectively collected, from 2007 to 2014, the diagnostic pathology, according to the World Health Organization classification, 2008, clinical features and survival of 4056 patients who were newly diagnosed with NHL...
March 23, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28332734/existence-of-jak2-mutation-19%C3%A2-years-prior-to-the-development-of-overt-polycythemia-vera
#11
LETTER
Yutaka Shimazu
No abstract text is available yet for this article.
March 23, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28332724/efficacy-and-safety-of-biosimilar-epoetin-alpha-in-patients-with-chronic-lymphoid-neoplasms-and-chemotherapy-induced-anaemia-an-observational-retrospective-monocentric-analysis
#12
Alessandro Broccoli, Lisa Argnani, Vittorio Stefoni, Letizia Gandolfi, Pier Luigi Zinzani
Epoetin biosimilars are an alternative to originator erythropoietic agents in the treatment of chemotherapy-induced anaemia; however, their effects in patients with lymphoproliferative disorders remain unclear. This analysis examined the response of patients with lymphoproliferative disorders experiencing chemotherapy-induced anaemia to 4- or 8-week treatment with the biosimilar epoetin alpha. Treatment was initiated at first occurrence of haemoglobin (Hb) < 10 g/dL during chemotherapy and was stopped when Hb was >11 g/dL, when chemotherapy was completed, or in case of transfusion dependency...
March 23, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28317148/bortezomib-induced-peripheral-neuropathy-a-genome-wide-association-study-on-multiple-myeloma-patients
#13
Chiara Campo, Miguel Inacio da Silva Filho, Niels Weinhold, Seyed Hamidreza Mahmoudpour, Hartmut Goldschmidt, Kari Hemminki, Maximilian Merz, Asta Försti
The proteasome-inhibitor bortezomib was introduced into the treatment of multiple myeloma more than a decade ago. It is clinically beneficial, but peripheral neuropathy (PNP) is a side effect that may limit its use in some patients. To examine the possible genetic predisposing factors to PNP, we performed a genome-wide association study on 646 bortezomib-treated German multiple myeloma patients. Our aim was to identify genetic risk variants associated with the development of PNP as a serious side effect of the treatment...
March 20, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28219112/brentuximab-vedotin-in-relapsed-refractory-hodgkin-lymphoma-the-hellenic-experience
#14
Maria K Angelopoulou, Theodoros P Vassilakopoulos, Ioannis Batsis, Ioanna Sakellari, Konstantinos Gkirkas, Vasiliki Pappa, Panagiota Giannoulia, Ioannis Apostolidis, Christos Apostolopoulos, Paraskevi Roussou, Panayiotis Panayiotidis, Maria Dimou, Marie-Christine Kyrtsonis, Maria Palassopoulou, Georgios Vassilopoulos, Maria Moschogiannis, Christina Kalpadakis, Dimitrios Margaritis, Alexander Spyridonidis, Eurydiki Michalis, Konstantinos Anargyrou, Panagiotis Repousis, Eleutheria Hatzimichael, Zoi Bousiou, Elias Poulakidas, Dimitrios Grentzelias, Nikolaos Harhalakis, Gerassimos A Pangalis, Achilles Anagnostopoulos, Panagiotis Tsirigotis
This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty-seven patients received BV after autologous stem cell transplantation failure, whereas 28 patients were treated with BV without a prior autologous stem cell transplantation, due to advanced age/comorbidities or chemorefractory disease...
February 20, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28219109/the-use-of-braf-v600e-mutation-specific-immunohistochemistry-in-pediatric-langerhans-cell-histiocytosis
#15
Leomar Y Ballester, Miguel D Cantu, Karen P H Lim, Stephen F Sarabia, Lizmery Suarez Ferguson, C Renee Webb, Carl E Allen, Kenneth L McClain, Carrie A Mohila, Jyotinder N Punia, Angshumoy Roy, Dolores H López-Terrada, M John Hicks, Kevin E Fisher
BRAF p.V600E mutations are detected in greater than 50% of pediatric Langerhans cell histiocytosis (LCH) lesions. However, the use of mutation-specific BRAF V600E immunohistochemistry (IHC) as a surrogate for molecular testing in pediatric LCH is unknown. We tested the mutation-specific BRAF V600E monoclonal antibody (clone VE1) in formalin-fixed, paraffin-embedded LCH samples from 26 pediatric patients (14 males and 12 females, ages 7 mo-17 y) using allele-specific real-time polymerase chain reaction (PCR) with a limit of detection of 0...
February 20, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28156055/combination-of-rituximab-and-nonpegylated-liposomal-doxorubicin-r-npld-as-front-line-therapy-for-aggressive-non-hodgkin-lymphoma-nhl-in-patients-80%C3%A2-years-of-age-or-older-a-single-center-retrospective-study
#16
Giuseppina Ricciuti, Erica Finolezzi, Stefania Luciani, Elena Ranucci, Massimo Federico, Marta Di Nicola, Isaia Antonio Luca Zecca, Francesco Angrilli
The incidence of non-Hodgkin lymphoma in patients 80 years of age or older is 50 times higher than in 20- to 24-year-olds. Very elderly patients are often not treated with standard immunochemotherapy because of poor performance status, comorbidities, and toxicity concerns. We retrospectively analyzed data for 29 patients diagnosed with diffuse large B-cell lymphoma or grade 3B follicular lymphoma and treated with rituximab in combination with nonpegylated liposomal doxorubicin between January 2010 and August 2015...
February 3, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28156016/severe-pneumonia-associated-with-ibrutinib-monotherapy-for-cll-and-lymphoma
#17
Natalia Kreiniz, Jacob Bejar, Aaron Polliack, Tamar Tadmor
In recent years, there have been major advances in the treatment of chronic lymphocytic leukemia (CLL) particularly since the development of novel therapeutic agents, mostly "biological drugs." One of the obvious advantages of these agents is the decreased rate of infectious complications occurring during the course of therapy, compared to the use of standard immuno-chemotherapy regimens. Here, we describe 3 patients with CLL and 1 with mantle cell lymphoma who developed severe life-threatening pneumonias, during monotherapy with ibrutinib...
February 3, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28156010/refractoriness-to-immunochemotherapy-in-follicular-lymphoma-predictive-factors-and-outcome
#18
Marc Sorigue, Santiago Mercadal, Sara Alonso, Ruben Fernández-Álvarez, Olga García, Miriam Moreno, Helena Pomares, Miguel Alcoceba, Esther González-García, Cristina Motlló, Eva González-Barca, Alejandro Martin, Anna Sureda, Dolores Caballero, Josep-María Ribera, Juan-Manuel Sancho
Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed with stage II to IV follicular lymphoma between 2002 and 2014 and treated with first-line ICT in 4 Spanish institutions were analyzed. Those with no response or progression or relapse within 6 months of first-line response assessment were considered ICT refractory...
February 3, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28297105/retraction-statement-flt3-beyond-good-and-evil-by-carlos-cortes-penagos-et-al
#19
(no author information available yet)
No abstract text is available yet for this article.
March 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28297104/retraction-statement-overview-of-recent-trends-in-diagnosis-and-management-of-leptomeningeal-multiple-myeloma-by-mahender-r-yellu-jessica-m-engel-abhimanyu-ghose-and-adedayo-a-onitilo
#20
journal
journal
28626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"